Does Finerenone Meaningfully Change HFmrEF/HFpEF Care After SGLT2 Uptake in Malaysia?

Which patients with confirmed HFpEF should be referred for consideration of finerenone?

Refer confirmed HFpEF patients with persistent symptomatic chronic HF for specialist review if you are considering adding an MRA, especially where finerenone may be preferable to spironolactone because of adverse effects, intolerance, or concern about endocrine side effects. Do not refer solely for finerenone if HFpEF

Why are potassium and eGFR rechecked four weeks after starting finerenone?

This is mainly a safety and dose-adjustment check. Finerenone is a non-steroidal mineralocorticoid receptor antagonist, so the early concerns after initiation are hyperkalaemia and a fall in eGFR/renal function. The product information recommends checking serum potassium at 4 weeks after starting, and NICE-associated p

Which residual-risk phenotype is most likely to gain meaningful absolute benefit from finerenone after SGLT2 therapy?

The residual-risk phenotype most likely to derive meaningful absolute benefit from finerenone despite prior SGLT2 therapy is the patient with persistent, clinically significant residual albuminuria/proteinuria—especially UACR ≥300 mg/g (A3 albuminuria), and particularly when this coexists with reduced eGFR/high KDIGO r

How should finerenone be layered with RAAS blockade, loop diuretics, and SGLT2 inhibitors without excessive hyperkalaemia?

Assuming adult patients with T2D + albuminuric CKD (the evidence-based indication for finerenone), the safest sequence is: 1. Maximise tolerated single-agent RAAS blockade with either an ACE inhibitor or an ARB — not dual ACEi+ARB. 2. Add an SGLT2 inhibitor early if eligible, because it is guideline-based cardiorenal t

Should finerenone replace spironolactone in HFmrEF/HFpEF, or be reserved for selected cardiorenal phenotypes?

Finerenone should not currently be viewed as a blanket replacement for spironolactone in all HFmrEF/HFpEF. The most defensible current position is: - Use finerenone preferentially in selected cardiorenal phenotypes, especially HFmrEF/HFpEF with CKD and type 2 diabetes, where it already has established kidney/CV outcome